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Hydrogen sulfide (H2S) is produced endogenously in vivo and
has multiple effects on signaling pathways and cell function.
Mitochondria can be both an H2S source and sink, and many of
the biological effects of H2S relate to its interactions with mito-
chondria. However, the significance of mitochondrial H2S is
uncertain, in part due to the difficulty of assessing changes in its
concentration in vivo. Although a number of fluorescent H2S
probes have been developed these are best suited to cells in cul-
ture and cannot be used in vivo. To address this unmet need we
have developed a mitochondria-targeted H2S probe, MitoA,
which can be used to assess relative changes in mitochondrial
H2S levels in vivo. MitoA comprises a lipophilic triphenylphos-
phonium (TPP) cation coupled to an aryl azide. The TPP cation
leads to the accumulation of MitoA inside mitochondria within
tissues in vivo. There, the aryl azido group reacts with H2S to
form an aryl amine (MitoN). The extent of conversion of MitoA
toMitoN thus gives an indication of the levels of mitochondrial
H2S in vivo. Both compounds can be detected sensitively by liq-
uid chromatography tandem mass spectrometry (LC-MS/MS)
analysis of the tissues, and quantified relative to deuterated
internal standards. Here we describe the synthesis and charac-
terization of MitoA and show that it can be used to assess
changes in mitochondrial H2S levels in vivo. As a proof of prin-
ciple we used MitoA to show that H2S levels increase in vivo
during myocardial ischemia.
There is considerable interest in the biological roles of hydro-
gen sulfide (H2S), both as an endogenously produced modula-
tor of mammalian metabolism and for its potential biomedical
effects when generated pharmacologically (1–3). Changes in
endogenous H2S levels have been claimed to impact on a
diverse range of physiological processes, including neuronal
function, blood pressure, angiogenesis, oxygen sensing, inflam-
mation, and mitochondrial energy production (4–16), and
exposure toH2S can induce a suspended animation-like state in
mice (17), but not in larger animals (18, 19).
Within mammals there are three main enzymatic sources of
H2S: cystathionine -synthase and cystathionine -lyase in the
cytosol, and mitochondrial 3-mercaptopyruvate sulfurtrans-
ferase in conjunction with cysteine aminotransferase (Fig. 1A)
(20). Once generated, H2S can be oxidized by sulfide:quinone
oxidoreductase (SQR)4 in the mitochondrial inner membrane,
passing electrons to the CoQ pool, and in parallel generating
glutathione persulfide in the matrix, which is further metabo-
lized to thiosulfate/sulfite/sulfate in the mitochondrial matrix
and intermembrane space (21, 22) (Fig. 1A).
The biological activity of H2S arises from four interrelated
processes: protein persulfidation, binding to metalloprotein
centers (most notably, inhibition of cytochromeoxidase), inter-
action with NO signaling pathways, and as an antioxidant (14,
20). Protein persulfidation is a recently emerging mode of
reversible posttranslational modification (PTM) of protein thi-
ols in whichH2S can react with a disulfide or a sulfenic acid, but
not unmodified protein thiols, to form a persulfidated protein
thiol (PrSSH), which can be reduced back to a thiol by the glu-
tathione or thioredoxin systems (23, 24). This reversible PTM
can in principlemodify protein activity in a similar way to other
PTMs, or can act as a releasable pool of H2S; however, the
extent and physiological significance of protein persulfidation
is still emerging. H2S can also inhibit cytochrome oxidase (25),
which is why high concentrations of H2S are toxic, but whether
these interactions with cytochrome oxidase or other heme pro-
teins are of physiological or pharmacological importance is
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unclear.H2S signaling is intimately interwovenwith that ofNO,
due to the formation ofHSNOandother intermediates, and it is
likely that protein modification by persulfidation and S-nitro-
sation are facets of a general signaling pathway (26, 27). Finally,
H2S may also contribute to antioxidant defenses, by reacting
directly with oxidants, or indirectly through its interactions
with protein thiols (20, 28).
AbnormalH2S levels have been reported in a range of pathol-
ogies including Down syndrome (29), diabetes (30), liver cir-
rhosis, and in ethylmalonic acid encephalopathy, which occurs
due tomutation to ETHE1 (31). However, the factors thatmod-
ify H2S levels in vivo under normal and pathological conditions
are obscure. In addition, the contribution of H2S generation to
the efficacy of pharmacological agents that release H2S is
uncertain. Therefore, understanding how the levels of H2S
change in vivo is vital to understanding its roles in physiology,
pathology, and pharmacology.
There are a number of methods to assess H2S in cells using
fluorescent probes that allow real-time detection of changes in
H2S levels (32–40). Although thesemethods can be applied to the
surfaces of animals (41), and to blood ex vivo (42), they cannot be
used in whole animals in vivo. Consequently, there are consider-
able uncertainties about howH2S tissue levels change in response
to physiological, pathological, or pharmacological events. These
uncertainties are amajor impediment to better understanding the
biological roles of H2S and its downstream targets.
To overcome this obstacle, we have developed MitoA, a
mitochondria-targeted mass spectrometry probe for H2S
detection in vivo (Fig. 1B). The probe comprises an H2S-sensi-
tive aryl azide moiety coupled to the lipophilic triphenylphos-
phonium (TPP) cation (Fig. 1B). The TPP cation targets a wide
range of bioactive and probe compounds to mitochondria in
vivo in response to the mitochondrial membrane potential (43,
44), and thus should lead to the rapid uptake of MitoA into
Figure 1. Overview of endogenous H2S production and rationale for its detection by MitoA. A, overview of H2S metabolism (sulfur-containing com-
pounds in bold). CBS, cystathionine -synthase; CSE, cystathionine -lyase; CAT, cysteine aminotransferase; GSSH, glutathione persulfide; 3-MP, 3-mercapto-
pyruvate; 3-MST, 3-mercaptopyruvate sulfurtransferase. B, reaction of MitoA with H2S to form MitoN. C, model of uptake of MitoA into mitochondria in vivo,
followed by its conversion toMitoN upon reactionwith H2S. The subsequent extraction ofMitoA andMitoN from the tissue and analysis by LC-MS/MS enables
changes in the levels of H2S in vivo to be inferred.
Measuring H2S withMitoA
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mitochondria in vivo.Within themitochondrial matrix the aryl
azide moiety is intended to react with H2S to form the aryl
amine, MitoN (Fig. 1B). This chemistry is based on that of
widely usedH2S-sensitive fluorescent probes, which rely on the
reaction of a non-fluorescent aryl azide to give a fluorescent aryl
amine (33, 37, 45, 46). The reaction occurs by initial nucleo-
philic attack of HS on the electrophilic terminal nitrogen of
the aryl azide, followed by a rate-determining reaction with a
secondHS, formingHS2, N2, and the aryl amine (37) (Fig. 1B).
Thus, MitoA can be injected into animals and the extent of
generation of the exomarker MitoN will depend on the levels
of H2S within mitochondria in vivo. Similar exomarker
approaches have been used in vivo to assess hydrogen peroxide
using MitoB (47, 48), and glyoxals through MitoG (49, 50). To
analyze MitoA and its conversion to MitoN, both are extracted
from animal tissue and then analyzed by LC-MS/MS relative to
deuterated internal standards (Fig. 1C). Because MitoA is mainly
present within mitochondria in vivo, it will report on the local
concentrationofH2Swithinmitochondria.However,becauseH2S
diffuses rapidly across cellularmembranes,H2S levels in themito-
chondria are likely to reflect or influence overall changes in H2S
within cells in vivo. Herewe report the development ofMitoAand
show that it can be used to assess changes in H2S in vivo.
Results and discussion
Reaction ofMitoAwith H2S to formMitoN
We first determined whether MitoA reacted with H2S to
formMitoN by measuring the effect of H2S on the UV absorp-
tion spectra of MitoA over time (Fig. 2A). Addition of NaHS,
Figure2.ReactionofMitoAwithH2Sto formMitoN.A,UV-visual absorbancespectraofMitoAreactingwithNaHS.MitoA (50M) inKClbufferwasmixedwith5mM
NaHSand spectrawere takenevery 15min. The inset shows spectra of pureMitoAandMitoN (25Meach).B, RP-HPLCanalysis ofMitoA,MitoN, and its reactivitywith
H2S. Standards of 10 nmol ofMitoA (upper trace) or MitoN (middle trace) were separated by RP-HPLC. For the lower traceMitoA (100M) in KCl buffer was incubated
overnightwith 1mMNaHS at room temperature. Then 5 nmol eq of startingMitoAwas analyzed by RP-HPLC. Spiking theNaHS-treatedMitoAwithMitoN increased
theMitoNpeak (data not shown).C, mass spectra ofMitoA,MitoN, orMitoA incubated overnightwithNaHS.Mass spectrawere taken ofMitoA (100M),MitoN (100
M),orMitoA(100M) incubatedwith1mMNaHSinKClbuffer,pH7.2,overnightat roomtemperature.Sampleswerediluted in20%ACN,0.1%FAandanalyzedwithin
5 h. Predicted m/z: MitoA, [C28H26N4OP]
  465.18; nitrene from neutral loss of N2, [C28H26N2OP]
  437.17; MitoN, [C28H29N2OP]
  439.19. The MS of MitoA
incubated at room temperature overnight was the same as that for freshly preparedMitoA (data not shown).D, time-resolved analysis of the reaction ofMitoAwith
H2S. MitoA (100M) wasmixedwith 2.5mMH2S in 300mM ammonium carbonate, pH 7.4, and sprayed continuously over 45min into an ultra high resolutionmass
spectrometer (maXis Bruker Daltonics). Spectra at selected time points are shown.Asterisk shows the nitrene formed fromMitoA by the neutral loss of N2.
Measuring H2S withMitoA
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which rapidly generates H2S (pKa 6.8 (51)), led to the gradual
conversion of MitoA to MitoN. RP-HPLC analysis of MitoA
following overnight incubation with excess NaHS showed its
complete conversion to MitoN (Fig. 2B). We could readily
detect MitoA andMitoN by mass spectrometry (MS) and their
spectra matched those predicted from the natural isotope dis-
tribution (supplemental Fig. S2). There was decomposition of
MitoA ([C28H26N4OP]; predictedm/z 465.18) by neutral loss
of N2 to form the nitrene ([C28H26N2OP]; predicted m/z
437.17), the extent of which depended on MS conditions (Fig.
2C). MS analysis of MitoA after overnight incubation with
excess NaHS showed formation of MitoN ([C28H29N2OP];
predicted m/z 439.19) further confirming that MitoA reacts
with H2S to form only MitoN (Fig. 2C); under these MS condi-
tions only the nitrene product of MitoA was found. When the
reaction of MitoA with H2S was monitored continuously using
time-resolved MS, where both MitoA and its nitrene product
were observed, the gradual loss ofMitoA and the accumulation
of MitoN were seen over time, consistent with MitoA reacting
selectively with H2S to generate MitoN (Fig. 2D).
The interaction of MitoA with other potential reactive spe-
cies that it may encounter in vivo was assessed by RP-HPLC
(Table 1). None of the tested compounds reacted to any signif-
icant extent with MitoA to form MitoN (Table 1): the greatest
conversion of MitoA to MitoN was 7.9% and required incuba-
tion with 10 mM glutathione for 24 h. A significant potential
confounder for the selectivity ofMitoA forH2S is the possibility
of its reacting with low molecular weight and protein persul-
fides. Therefore we next assessed the direct reactivity of MitoA
with NAP-SSH, a lowmolecular weight persulfide derivative of
N-acetylpenicillamine (NAP) (24, 52). A complication of ana-
lyzing persulfides is that they spontaneously release H2S, mak-
ing it difficult to separate the reaction of MitoA with H2S from
that with the persulfide itself (24). To address this, we com-
pared the reaction of MitoA with NAP-SSH to that of MitoA
with the same concentration of H2S (supplemental Fig. S3).
These experiments showed the expected reaction of MitoA
with H2S with formation of MitoN, whereas under the same
conditions the reaction of MitoA with NAP-SSH to form
MitoN was negligible (supplemental Fig. S3). Furthermore, the
incubation of 5 M persulfidated human serum albumin with
10 M MitoA led to negligible (7%) consumption of MitoA
over 4 h at room temperature (data not shown), most probably
due to spontaneous decay of persulfides to release H2S (53).
We next measured the rate of reaction of MitoA with H2S
from the time-dependent disappearance of the MitoA peak at
270 nm and the appearance of a new peak at 306 nm due to
MitoN (Fig. 3A). The absorption maxima for the non-TPP aro-
matic rings were identified using 4-azido-N-(hex-1-yl)benz-
amide and 4-amino-N-(hex-1-yl)benzamide, which are ana-
logues of MitoA and MitoN, respectively, but without the TPP
targeting group. We then incubated MitoA with known con-
centrations ofH2S andmeasured the formation ofMitoNat 306
nm (Fig. 3B). From these we were able to plot the observed
initial rate constant (kobs) forMitoN formation against the con-
centration ofH2S and calculate a rate constant: 0.16 0.03 M1
s1 at 22 °C (Fig. 3C). This compares with literature rates for
the reaction of H2S with phenyl azides: 0.12 M1 s1 at 10 °C
and 0.95 M1 s1 at 25 °C (37). One concern about the use of
MitoA is that its reaction consumes H2S and generates H2S2
(37), thereby potentially disruptingH2S signaling pathways and
altering protein persulfidation. Hence the slow reaction of
MitoA with H2S is advantageous because it allows selective
detection, while alsominimizing disruption to endogenousH2S
signaling pathways. Together these data indicate that, in agree-
ment with other aryl azides (45, 46), MitoA reacts selectively
with H2S and therefore that the conversion of MitoA toMitoN
can be used to assess H2S in vivo.
Analysis of MitoA andMitoN by LC-MS/MS
To be useful as an in vivo mass spectrometric probe MitoA
and MitoN have to be extracted from tissues and analyzed by
LC-MS/MS, relative to deuterated internal standards (IS) (47–
49). To establish the LC-MS/MS assaywe first determined frag-
mentation conditions that enabled sensitive detection ofMitoA
and MitoN, and their deuterated internal standards (Fig. 4A).
For the analysis of MitoA we took into account the neutral loss
of N2 from MitoA to generate the nitrene, which under these
conditions was complete upon entrance to the first mass spec-
trometer quadrupole. Using the transitions shown in Fig. 4Awe
could detect MitoA and MitoN, and their deuterated IS, selec-
tively by LC-MS/MS (Fig. 4B). Hence we were able to generate
standard curves for MitoA andMitoN down to picomole levels
(Fig. 4C).
A potential concern for the LC-MS/MS analysis is that
MitoA might react with H2S generated upon homogenization
and extraction of tissues, for example, by release of labile sulfur
from iron-sulfur centers. The possibility of H2S release was
minimized by omitting acid during tissue extraction. Even so, to
Table 1
MitoA (10 M) was incubated with each substance for the indicated
time and temperature in KCl buffer and analyzed by RP-HPLC
Dimethyl trisulfide was dissolved in 70% EtOH. For NO, DetaNONOate (50 M)
was disolved inKCl buffer, which had been deoxygenated by bubblingwith argon for
30 min. Superoxide was generated using 5 milliunits/ml of xanthine oxidase and 1
mM hypoxanthine in KCl buffer and its production quantified as the SOD-sensitive
reduction of ferricytochrome c. Reactivity (MitoN 100)/(MitoNMitoA).
Concentration
Incubation
condition Reactivity
%
H2S 100 M 4 h, RTa 94
Glutathione 5 mM 24 h, 37 °C 7.3
5 mM 4 h, 37 °C 2.2
10 mM 24 h, 37 °C 7.9
10 mM 4 h, 37 °C 4.6
Cysteine 2 mM 4 h, RT LODb
Dimethyl trisulfide 100 M 4 h, RT LOD
Lipoic acid 100 M 4 h, RT LOD
Dihydrolipoic acid 100 M 4 h, RT LOD
Na2S2O3 100 M 4 h, RT LOD
Na2S2O4 100 M 4 h, RT LOD
NADH 5 mM 4 h, RT LOD
NADPH 5 mM 4 h, RT LOD
NaSCN 100 M 4 h, RT LOD
NaNO2 100 M 4 h, RT LOD
NO 50 M 4 h, RT LOD
ONOO 100 M 4 h, RT 1.25
H2O2 100 M 4 h, RT LOD
t-BuOOH 100 M 4 h, RT LOD
O2. 1.79 nmol of cytochrome
c/min
4 h, RT LOD
HOCl 100 M 4 h, RT LOD
a RT, room temperature.
b LOD, limit of detection.
Measuring H2S withMitoA
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assess whether an artifactual reaction with released H2S could
occur, we incubated MitoA in tissue extraction medium sup-
plemented with H2S for up to 4 h, and then measured MitoN
formation by LC-MS/MS. As expected, this showed some con-
version of MitoA to MitoN, but with a very small (0.02)
increase in the MitoN/MitoA ratio (supplemental Fig. S4).
Considering the high H2S concentration added, and that the
incubation time of 4 h was far longer than that used during
conventional extraction, we conclude that the artifactual con-
version of MitoA to MitoN during tissue extraction is negligi-
ble. In any case such a potential artifact would be equal for all
tissue samples and therefore would not affect comparisons. To
conclude, we have established a sensitive LC-MS/MS assay for
H2S that can be applied to tissues.
Uptake ofMitoA andMitoN bymitochondria and cells
To be useful for the analysis of H2S in vivo, MitoA must be
taken up into mitochondria in response to the membrane
potential. To see if this occurred we next assessed the accumu-
lation of MitoA and MitoN by isolated mitochondria using a
triphenylphosphonium (TPP)-selective electrode (54) (Fig. 5,A
andB). Both probes accumulated insidemitochondria650- to
1,000-fold in response to the membrane potential and this
uptake was reversed by abolishing the mitochondrial mem-
brane potential with the uncoupler FCCP. Therefore, MitoN
andMitoA are taken up by energizedmitochondria as expected
for TPP compounds. To determine whether MitoA was accu-
mulated within cells we first established that the toxicity of
MitoA or MitoN to cells in vitro was negligible at concentra-
tions up to 12.5 M, determined by following the effects of the
compounds on cell proliferation (supplemental Fig. S5). To
assess the uptake of MitoA into cells, we incubated HCT116
cells with MitoA and measured the amounts taken up by the
cells over time by LC-MS/MS (Fig. 5C). This showed that
MitoA was taken up into cells over time, coming to a steady
state after1 h. Over this time the amount ofMitoN generated
was small (Fig. 5C), consequently the MitoN/MitoA ratio
stayed low and constant throughout the incubation (Fig. 5D).
Therefore MitoA is taken up by cells and, at least under these
conditions, there was low MitoN formation.
Reactivity and stability of MitoA in tissue homogenates
MitoA is designed to assess H2S in tissues in vivo. To deter-
mine whether there were any enzymatic processes in tissues
that could convert MitoA to MitoN in the absence of H2S, we
incubatedMitoAwith liver homogenates andmeasuredMitoN
formation (Fig. 6A). Under these conditions enzymes are avail-
able to react with MitoA, but the lack of tissue and cell archi-
tecture means that any H2S generated will diffuse away. Incu-
bation of MitoA with a liver homogenate led to a negligible
MitoN formation (Fig. 6A) and no increase in the MitoN/
MitoA ratio (Fig. 6B), even though the reaction proceeded read-
ily when H2S was added (Fig. 6, A and B). Similarly, incubation
ofMitoNwith a liver homogenate in the presence or absence of
H2S led to very little loss of the compound (Fig. 6C). Together
these data suggest thatMitoA conversion toMitoN in tissues is
negligible in the absence of H2S, and that once formedMitoN is
stable.
Response of MitoA to H2S in ischemic liver sections
Thenext stepwas to see howMitoA responded to an increase
in endogenous H2S within a tissue. To assess this we incubated
liver tissue sections with various concentrations of MitoA at
4 °C, designed to mimic conditions during organ storage for
transplantation (55, 56). MitoA was taken up into the tissue
sections over time (Fig. 6D). Under these conditions the tissue
will be largely ischemic, as there is no perfusion and O2 will be
depleted by the oxidation of endogenous substrates. The lack of
O2will block the activity of themitochondrial SQR,which is the
majorway inwhichH2S is degraded in vivo (Fig. 1A). It is known
that when the activity of the SQR is decreased by depletion of
the mitochondrial CoQ pool, that there is an accumulation of
H2S within mice in vivo (57). Thus, under ischemic conditions
Figure 3. Rate of reaction ofMitoAwith H2S to formMitoN. A, differential
time-resolved spectra where 40 M MitoA was mixed with 2.5 mM H2S, with
MitoA serving as the blank. The spectra illustrate the time-dependent disap-
pearance of the MitoA peak at270 nm and the appearance of a new peak
assigned to MitoN at 306 nm. B, kinetic traces at 306 nm obtained for the
reaction of 40 M MitoA with increasing concentrations of H2S, the absor-
bance was observed over 6 min at 306 nm using a Hewlett Packard 8452A
Diode Array Spectrophotometer under pseudo-first order conditions. C, plot
of kobs versus [H2S]. The experiments were performed in 300 mM potassium
phosphate buffer, pH 7.4, at 22 °C in triplicates.
Measuring H2S withMitoA
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the inhibition of SQR is expected to increase H2S levels. Fur-
thermore, H2S production by the mitochondrial 3-mercapto-
pyruvate sulfurtransferase enzyme is driven by the reduced
form of thioredoxin, which will also increase in concentration
upon ischemia (58). Therefore it is likely that there will be an
increase in H2S levels in these liver sections upon ischemia.
To see if this increase in H2S led to MitoN formation in the
ischemic liver sections, we measured MitoN levels over time
and expressed these relative toMitoA. This showed an increase
in the MitoN/MitoA ratio over time (Fig. 6E), consistent with
increased H2S formation in ischemic organs over time. Impor-
tantly, the MitoN/MitoA ratios at a given time point were sim-
ilar for all initial MitoA concentrations used. Thus the ratio-
metric analysis of MitoN relative to MitoA corrects for
differences in MitoA content and suggests that the MitoA/
MitoN ratio is a robust measure of changes in H2S levels.
Uptake andmetabolism ofMitoA andMitoNwithin tissues in
vivo
Previously developed exomarkers such as MitoB were
administered to mice as a single intravenous (i.v.) bolus injec-
tion (47). This approach enabled the compounds to be very
rapidly accumulated within tissues in vivo, after which they are
gradually lost over the following hours. This protocol gives suf-
ficient time for the accumulated compound (e.g.MitoB) to react
with its target (e.g.H2O2) to form an exomarker (e.g.MitoP). To
see if MitoA could also be used in this way, we assessed MitoA
distribution within mouse tissues following a single i.v. injec-
tion (Fig. 7, A and B). This showed rapid clearance of MitoA
from the blood and its accumulation into the heart and liver,
but not the brain, as expected for TPP compounds in mice (59,
60) (Fig. 7A). The kidney accumulated more MitoA than the
other tissues, presumably due to direct removal of the initial
bolus from the circulation, as well as redistribution of MitoA
from other tissues over time (Fig. 7B). MitoAwas gradually lost
from the tissues over time (Fig. 7, A and B), consistent with
other TPP compounds (59). These findings suggest that MitoA
is accumulated rapidly by tissues and is retained long enough to
respond to local levels of H2S.
To report on H2S levels within tissues in vivoMitoA should
only be converted toMitoNby reactionwithH2S, withminimal
side reactions. To assess this we injected MitoA into mice and
1 h later isolated the liver. The liver was chosen because it read-
ily accumulates MitoA (Fig. 7A) and has extensive xenobiotic
metabolism. Thus, if MitoA is biotransformed to compounds
other thanMitoN in vivo the liver should demonstrate this bio-
transformation. Extraction andMS analysis of the liver showed
Figure 4. Detection ofMitoA andMitoN by LC-MS/MS. A, the transitions used for analysis of MitoA andMitoN, and their deuterated derivatives, are shown.
B, typical chromatograms showing them/z transitionsmeasured simultaneously for 50pmol ofd15-MitoA,MitoA,d15-MitoN, orMitoN. Each trace is normalized
to the highest total ion count peak within that trace. C, typical standard curves for MitoA and MitoN detection by LC-MS/MS. Samples were prepared in 20%
ACN, 0.1% FA and contained known MitoA or MitoN concentrations and their deuterated internal standards. Each point is mean  range of duplicate
measurements.
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a large number of compounds (Fig. 7C, i). Analysis byMS/MSat
the transition diagnostic for MitoA (437 	 183) showed the
presence of MitoA (Fig. 7C, ii). Similarly, analysis at the transi-
tion diagnostic for MitoN (439 	 183) showed some MitoN
formation in vivo (Fig. 7C, iii). These mass spectra were identi-
cal to those of pureMitoA andMitoN (Fig. 7C, ii and iii, insets).
To see if MitoA and MitoN were metabolized in the liver to
other TPP containing molecules, we next carried out a precur-
sor scan of the extract to identify all compounds that frag-
mented to a productwithm/z 183, diagnostic of aTPP-contain-
ing compound (47, 61). In the liver extract the only precursor
molecules that gave a product ion of m/z 183 corresponded to
the nitrene product ofMitoA upon neutral loss of N2 (m/z 437),
MitoN (m/z 439), with a small amount of intact MitoA (m/z
465) (Fig. 7C, iv). This precursor ion pattern was similar to that
of pure MitoA (Fig. 7C, iv, inset).
Another potential concern is whether MitoN could be fur-
ther metabolized in vivo, following its formation from MitoA.
To assess this we injectedMitoN intomice and 1 h later isolated
the liver and analyzed this extract by MS analysis (Fig. 7D, i).
Analysis by MS/MS at the transition diagnostic for MitoN
(439	 183) showed the presence ofMitoN (Fig. 7D, ii), and the
spectrumwas identical to that of pureMitoN (Fig. 7D, ii, inset).
To see if MitoN was metabolized within the liver in vivo, we
next carried out a precursor scan of the extract to identify all
compounds that fragmented to a product with m/z 183, diag-
nostic of a TPP containing compound (47, 61). In the liver
homogenate the only parentmolecules that gave a daughter ion
ofm/z 183 corresponded toMitoN (m/z 439), with a small peak
at 455 (Fig. 7D, iii). This precursor ion pattern was similar to
that of pureMitoN (Fig. 7D, iii, inset). The precursor ion at 455
is a 16 shift from MitoN and may represent oxidation of
MitoN by addition of an oxygen atom. Even so, it suggests that
once formed MitoN is relatively stable and that any further
metabolism of MitoN is unlikely to affect the analysis of H2S in
vivo.
Use ofMitoA to analyze H2S in the ischemic heart in vivo
The increase in the MitoN/MitoA ratio in the ischemic liver
(Fig. 6E) is consistent with an increase in H2S in tissue during
ischemia. To extend this, we next focused on the heart as its
metabolism changes dramatically upon ischemia (62, 63). As a
first step to see whether there was any accumulation of H2S in
the ischemic heart we administeredMitoA tomice, isolated the
heart, and stored it under ischemic conditionsmimicking those
used for organ storage during transplantation (Fig. 8A). The
MitoN/MitoA ratio increased after 240 min ischemia, consis-
tent with elevated H2S during the ischemia inherent in organ
storage.
To explore further how H2S levels respond to ischemia we
next used the left anterior descending (LAD) model of acute
myocardial infarction. MitoA was injected into mice and then
Figure 5. Accumulation of MitoA and MitoN by isolated mitochondria
and cells. The uptake of MitoA (A) and MitoN (B) was examined in isolated
mitochondria (2 mg of protein/ml) incubated in KCl medium supplemented
with 4 g/ml of rotenone and 100 nM nigericin using a TPP-selective elec-
trode. The compounds were added in 1 M steps, followed by 10 mM succi-
nate and 500 nM FCCP. C, MitoA uptake by HCT116 cells. HCT116 cells were
plated at 250,000 cells/well (27,000 cells/cm2) in 6-well plates overnight
and then incubated with 10 M MitoA in DMEM containing 10% FBS and
antibiotics. At various times 1ml of supernatantwas removed for analysis, the
restwas discarded, and the cellswere rinsedwith 1ml of PBS and collectedby
scraping into 0.5ml of PBS and pelleted by centrifugation (16,000 g, 3 min,
room temperature). Cell pellets were snap frozen and stored at20 °C. Com-
pounds were extracted and quantified by LC-MS/MS. Results aremean S.E.
for n 3. MitoA levels in the supernatant did not change over 6 h (data not
shown). D, for the experiment in C, the level of MitoN in the cell pellets were
assessed in parallel with MitoA and the MitoN/MitoA ratio is shown.
Figure 6.MitoA andMitoNmetabolism in the liver ex vivo. A and B,MitoA
metabolism by a liver homogenate. MitoA (10 M) was incubated with vari-
ous amounts of liver homogenate, or with liver homogenate and NaHS (25
M), for 2 h at 37 °C. Samples were then analyzed by LC-MS/MS to quantify
MitoA (data not shown), MitoN (A), and the MitoN/MitoA ratio (B). Data are
mean  S.E., n  3. C, MitoN metabolism by a liver homogenate. MitoN (10
M) was incubated with various amounts of liver homogenate, or with liver
homogenate and NaHS (25M), for 2 h at 37 °C. Samples were then analyzed
by LC-MS/MS for MitoN. Data are mean S.E., n 3. D, uptake of MitoA by
liver sections. Rat liver sections of20 to 50 mg wet weight were incubated
with MitoA in University of Wisconsin solution at 4 °C. After incubation, the
tissue pieces were rinsed in PBS, dried, and snap frozen prior to quantifi-
cation of MitoA and MitoN by LC-MS/MS. Data show the accumulation of
MitoA over time and are mean  S.E., n  3. E, MitoN/MitoA ratio in liver
sections. The MitoN/MitoA ratio was determined over time in liver sec-
tions as described in D.
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cardiac ischemia was induced by closing off the LAD artery,
thus subjecting a large section of the left ventricle to ischemia.
In previous work we have shown that when the occlusion to the
LAD artery was removed after 30 min ischemia and the tissue
reperfused with oxygenated blood, there was extensive ische-
mia-reperfusion injury (63). This model thereby enables us to
use MitoA to assess variations of H2S levels during both ische-
mia and reperfusion. In comparing the formation of MitoN
through these changes it is important that MitoA is present in
the tissue for the same duration. To ensure this, we injected
MitoA at various time points before or after initiation of ische-
mia (Fig. 8B). Importantly, this protocol meant that MitoA was
exposed to a range of times of ischemia and reperfusion,
whereas always being present in the tissue for 40 min, thereby
facilitating comparison. In the LAD model only the left ventri-
cle is exposed to ischemia and reperfusion, however, as it was
unclear what effect ischemia in the left ventricle would have on
the right ventricle from the same mouse, the right ventricle
from the samemouse cannot act as a control. Therefore the left
and right ventricles from mice that underwent ischemia were
compared with the appropriate ventricle from MitoA-treated
normoxic mice.
When MitoA was injected into control mice in which the
hearts were not exposed to ischemia or reperfusion, analysis of
the right and left ventricles 40 min later showed a low MitoN/
MitoA ratio in both ventricles (Fig. 8C). When MitoA was
injected before reperfusion, the MitoN/MitoA ratio was in-
creased compared with normoxic hearts, presumably as
result of H2S present in the tissue before reperfusion. However,
administration 5 min after reperfusion resulted in the MitoN/
MitoA ratio similar to normoxic hearts. Furthermore, during
ischemia there was a dramatic increase in the MitoN/MitoA
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Figure 7. Uptake andmetabolism of MitoA in vivo. A and B,mice were injected with 50 nmol of MitoA and tissues were collected, extracted, and analyzed
by LC-MS/MS. Results aremean S.E., n 3. C, MitoA (50 nmol) was administered tomice. After 60min the liver was collected, extracted, and prepared as for
mass spectrometry (LC-MS/MS) but omitting the internal standards and analyzed by mass spectrometry by direct infusion at 5 l/min. C, i, shows the mass
spectrum of the liver extract. ii, shows the MS/MS spectrum of the liver extract assessed for MitoA (437	 183). The inset shows the MS/MS spectrum for pure
MitoA. iii, shows the MS/MS spectrum of the liver extract assessed for MitoN (439	 183). The inset shows the MS/MS spectrum for pure MitoN. iv, shows the
precursor scan of the liver extract assessed for precursor ions that generate a product ion ofm/z 183. The inset shows the precursor ion scan for pureMitoA.D,
MitoN (50nmol)was administered tomice. After 60min the liverwas collected, extracted into solvent, andprepared as formass spectrometry, but omitting the
internal standards, and analyzed by MS by direct infusion at 5 l/min. D, i, shows the mass spectrum of the liver extract. ii, shows the MS/MS spectrum of the
liver extract assessed for MitoN (439	 183). The inset shows theMS/MS spectrum for pureMitoN. iii, shows the precursor scan of the liver extract assessed for
precursor ions that generate a product ion of m/z 183. The inset shows the precursor ion scan for pure MitoN. For all spectra the maximum ion counts are
indicated on the spectra and all ion counts are expressed as % of the maximum.
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ratio in the left ventricle, but not in the right (Fig. 8C). The
MitoN/MitoA ratio increased the longer the duration of ische-
mia to which the left ventricle was exposed (Fig. 8C). Compar-
ison between the ischemic and non-ischemic zones of the heart
showed that the H2S increase was local to the ischemic tissue
area, and did not diffuse to surrounding tissue of the same
organ. Together, these findings are consistent with an increase
in H2S during ischemia that is rapidly reversed once oxygen is
reintroduced into the tissue upon reperfusion. Furthermore,
these findings indicate that MitoA can be used to assess
changes in H2S in vivo.
Conclusions
Herewe have applied the exomarker approach to the analysis
ofH2S in vivo. To do this we used thewell established chemistry
of aryl azides and their conversion to an amine on reaction with
H2S (33, 36, 46). The combination of this chemistry with mito-
chondria targeting by the TPP moiety led to its rapid uptake
into cells in vivowhere it is predicted to bemainly located in the
mitochondria. There, MitoA should react with H2S to form the
diagnostic exomarker MitoN. The chemical selectivity for H2S
of the MitoA probe was clear, and it did not react with other
potential factors found in biological environments. Most
importantly, it did not react directly with persulfides, suggest-
ing that in vivo it reports on free H2S independently of any
changes in the levels of protein or low molecular weight
persulfides.
The most important aspect of the development of MitoA is
that it enables the assessment of changes in H2S in vivo. This
exomarker approach has previously been used to infer levels of
evanescent species such as H2O2 in a range of living organisms,
where assessments ex vivo or in isolated cells would have intro-
duced confounding factors making the data hard to interpret.
The experimental constraints are similar with assessment of
Figure8.AssessmentofH2S in vivousingMitoA.A,MitoA in theheart during storage ex vivo.MitoA (50nmol)was administered tomice via tail vein injection.
The heart was removed after12min of warm ischemia. The hearts were then either snap frozen or stored for 240min on ice and then snap frozen. Samples
were analyzed by LC-MS/MS forMitoA andMitoN, and theMitoN/MitoA ratiowas calculated. Results aremean S.E., n 3. *, p 0.05 by Student’s two-tailed
t test. B, protocol for the LAD artery occlusion experiments. C, mice were injected with 50 nmol of MitoA prior to ischemia of the left ventricle induced by
occlusion of the LAD artery. At the end of the protocol the hearts were separated into right (normoxic) and left (normoxic or ischemic) ventricles, snap frozen,
and analyzed forMitoA andMitoN content by LC-MS/MS, enabling theMitoN/MitoA ratio to be calculated. Data aremean S.E., n 3. *, p 0.05; **, p 0.01;
***, p 0.001; ****, p 0.0001, by two-way analysis of variance followed by post hoc Bonferroni test.
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free H2S in tissues, and are in fact exacerbated due to the rapid
diffusion of H2S from in vitro systems, such as cell culture
where H2S rapidly disperses into the large amount of medium
above a cell monolayer and is then lost into the head space. In
contrast, in tissues the situation is quite different, where the
local architecture can enable a large build up of H2S. Conse-
quently, measurements of H2S levels within tissues in vivo
under normal and pathological conditions are essential to infer
the roles of H2S in vivo.
As a proof of principle to test MitoA in vivo, we assessed
changes in H2S in tissues undergoing ischemia/hypoxia. Ische-
mia is expected to lead to an increase in H2S due to the inhibi-
tion of H2S degradation by SQR that occurs in the absence of
O2. An advantage of thismodel to test the efficacy ofMitoAwas
that there was no intervention with an exogenous agent or H2S
donor, thus it indicates that MitoA can respond to H2S levels
that may arise in vivo under pathological conditions. These
findings also demonstrated that therewere dramatic changes in
H2S between the ischemic and normoxic regions of the heart,
and that the H2S levels rapidly returned to normal upon reper-
fusion with oxygenated blood. None of these assessments
would have been possible prior to the development of MitoA.
Interestingly, as well as enabling the testing of MitoA, these
findings suggested that H2S levels may be a significant aspect of
how tissues respond to ischemia and these changes in H2S will
be explored further as a potential ischemic signaling pathway.
There are a few limitations to the exomarker approach.
Because the ratio of MitoN to MitoA can only be determined
from tissue samples ex vivo, each time point requires killing a
mouse. Furthermore, the analysis is inevitably an average of
many different cells and mitochondria. Consequently, comple-
mentary techniques are required to assess changes in individual
cells and in real time. Another caveat is that many of the effects
of alteringH2Smetabolism are likely to be caused by changes in
protein persulfidation that will not be picked up directly by the
MitoA approach, which only responds to free H2S. Therefore it
is important in the future to develop related techniques to
assess protein persulfidation in parallel to the measurement of
free H2S. Finally, it is difficult to relate the MitoN/MitoA ratio
to the actual amount of H2S present in vivo.
In summary, we have developed a mass spectrometric probe
that will enable for the first time changes in the levels of H2S to
be assessed in vivo. Use of this probewill greatly facilitate inves-
tigations of the role of H2S in health and disease.
Experimental procedures
Chemical syntheses
MitoA and MitoN were synthesized from triphenylphos-
phine and the deuterated analogues, d15-MitoA and d15-MitoN,
from tri(pentadeuterophenyl)phosphine as shown in supple-
mental Fig. S1A. The triarylphosphines were each reacted with
1,3-diodopropane to give iodopropyl-TPP salts 1 and d15-1.
Displacement of the alkyl iodide by azide gave the azidopropyl-
TPP salts 2 and d15-2, and hydrogenation converted these into
the amines 3 and d15-3. The latter were coupled with 4-azido-
benzoic acid using diisopropylcarbodiimide in acetonitrile
(ACN) and the resulting amide precipitated from solution in
each case. Ion exchange then gave MitoA and d15-MitoA as
theirmesylate salts inmoderate yield. In a similar way, coupling
4-aminobenzoic acid followed by ion exchange gaveMitoN and
d15-MitoN as their mesylate salts. 4-Azido-N-(hex-1-yl)benz-
amide 4 and 4-amino-N-(hex-1-yl)benzamide 5, which are ana-
logues of MitoA and MitoN lacking the TPP targeting group,
were prepared for comparison (supplemental Fig. S1B). Further
details of the chemical syntheses are given under supplemen-
tary materials. Peroxynitrite was prepared according to Refs.
64 and 65. A persulfide analogue of S-nitrosopenicillamine,
NAP-SSH, was synthesized as described (52) and was prepared
as a 1 mM stock in 10 mM HCl at 4 °C.
Assessment of compound properties
MitoA and MitoN stock solutions (5 mM in ethanol (EtOH))
were stable for at least 6months at20 °C. Absorbance spectra
were carried out in 1-ml cuvettes in KCl buffer (120mMKCl, 10
mM Hepes and 1 mM EGTA, pH 7.2 (KOH)) using a Shimadzu
UV-2501PC UV-visible spectrophotometer. The molar extinc-
tion coefficient for MitoA at 267 nm in KCl buffer was calcu-
lated gravimetrically: 20.4 0.1 103 M1 cm1.
Reversed phase-high performance liquid chromatography
(RP-HPLC) was done using a Gilson 321 pump with attached
UV-visible 151 system (Gilson). Samples were filtered through
a 0.22-mpolyvinylidene difluoride (PVDF) filter (Millex, Mil-
lipore), loaded, and run over a C18 column (Jupiter 300 Å, Phe-
nomenex) with a Widepore C18 guard column (Phenomenex).
HPLC buffer A (0.1% (v/v) trifluoroacetic acid (TFA) in water)
and HPLC buffer B (0.1% (v/v) TFA/acetonitrile) were used
with the gradient: 0–2 min, 5% B; 2–17 min, 5–100% B; 17–19
min, 100% B; 19–22 min 100–5% B.
Cell culture
Cells (C2C12 or HCT116 from the American Type Culture
Collection) were incubated at 37 °C in a humidified atmo-
sphere of 95% air and 5% CO2 in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% (v/v) fetal bo-
vine serum (FBS) and 100 units/ml of penicillin and 100
g/ml of streptomycin.
Preparation of H2S solutions
Unless indicated otherwise, standard solutions of H2S were
prepared by dissolving NaHS in KCl buffer, the pH was re-ad-
justed to 7.2 and then the solutionwas aliquoted into tubeswith
no head space and kept on ice. The H2S concentration was
determined by the methylene blue assay (66).
Mitochondrial preparation and incubation
Liver mitochondria were prepared from female Wistar rats
killed by stunning and cervical dislocation, followed by homog-
enization of the liver and differential centrifugation in ice-cold
STE buffer (250 mM sucrose, 10 mM Tris, 1 mM EGTA, pH 7.4).
The protein concentration was determined by the biuret assay
using bovine serum albumin as a standard (67).
Extraction ofMitoA andMitoN
For cells, frozen pellets were thawed, vortexed, and resus-
pended in 210l of 95% acetonitrile (ACN) spikedwith internal
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standard (100 pmol of d15-MitoA and 100 pmol of d15-MitoN).
Following protein precipitation (30 min, 4 °C) and centrifuga-
tion (16,000  g, 10 min, room temperature) the supernatant
was filtered through a 0.22-m filter and dried under vacuum
(miVac Quattro concentrator; Genevac) and stored at20 °C.
For extraction from tissues, 50 mg wet weight tissue was
placed in a 2-ml Eppendorf tube containing 210l of 95%ACN
spiked with internal standards (100 pmol of d15-MitoA and 100
pmol of d15-MitoN). For the blood no further additions were
made, but for the tissues we added50l of beads (liver, brain,
and kidney, 0.5-mm diameter zirconium oxide beads; heart,
0.9–2.0-mm diameter stainless steel beads, both from Next
Advance) and homogenized for 3 min using a Bullet Blender
(Storm 24; Next Advance) at speed 8. Samples were centrifuged
(16,000  g, 10 min, room temperature), the supernatant was
transferred to a new Eppendorf tube. The pellet was re-ex-
tracted with 95% ACN, and the supernatants were pooled and
incubated for 30 min at 4 °C to precipitate proteins. After cen-
trifugation (16,000 g, 10 min, room temperature) the super-
natant was filtered and dried as above and stored at 20 °C.
Prior to analysis the samples were resuspended in 20% ACN,
0.1% FA, centrifuged (16,000  g, 10 min, room temperature),
and transferred to mass spectrometry vials (TrueViewTM
LCMS Certified, Waters).
LC-MS/MS analysis
For MS/MS analysis we used a triple-quadrupole mass spec-
trometer (Waters Xevo TQ-S under positive ion mode: source
spray voltage, 3.2 kV; cone voltage, 125 V; ion source tempera-
ture, 100 °C; collision energy, 75 V). Nitrogen and argon were
used as curtain and collision gas, respectively. MS fragmenta-
tion patterns were determined by direct infusion (5 nM at 50
l/min in 20% ACN, 0.1% FA). For LC-MS/MS analyses the
mass spectrometerwas connected in series to an I-classAcquity
LC system (Waters). Samples were stored in an autosampler at
4 °C and 2-l samples went into a 15-l flow-through needle
and RP-UPLC at 40 °C using an Acquity UPLC BEH C18 col-
umn (1  50 mm, 1.7 m; Waters) with a Waters UPLC filter
(0.2 m). MS buffers A (95% water, 5% ACN, 0.1% FA) and B
(90% ACN, 10% water, 0.1% FA) were infused at 200 l/min
using the following gradient: 0–0.3 min, 5% B; 0.3–3 min,
5–100%B; 3–4min, 100%B, 4.0–4.10, 100–105%B; 4.10–4.60
min, 5% B. Eluant was diverted to waste from 0 to 1 min and
from 4 to 4.6 min. Compounds were detected in multiple reac-
tions monitoring in positive ion mode. Under these conditions
MitoA underwent neutral loss of N2 to a nitrene, which was
used as the precursor ion. For quantification the following tran-
sitions were used: MitoA, 437 	 183; d15-MitoA, 452 	 191;
MitoN, 439	 183;d15-MitoN, 454	 191. Standard curveswith
known amounts of MitoA and MitoN were prepared, spiked
with IS, and extracted following the protocol outlined above.
The peak area ofMitoA,MitoN, and IS of samples and standard
curves were quantified using the MassLynx 4.1 software.
Liver homogenate incubations
Liver was collected from a female Wistar rat that had been
killed by stunning and cervical dislocation, and carried out in
accordance with the UKHomeOffice Guide on Animal Exper-
iments. The liver was transferred to ice-cold STE buffer, cut
into small pieces using a razor blade, washed in ice-cold KCl
buffer, and homogenized in aDounce homgenizer, and the pro-
tein concentration was determined by biuret assay.
Mouse experiments
Wild-type male C57BL/6J mice (8–10 weeks old) were
obtained from Charles Rivers Laboratories (UK). Mice were
housed under standard laboratory conditions with food and
water available ad libitum and experiments were carried out in
accordance with the UKHomeOffice Guide on Animal Exper-
iments andwere approved under Project Licenses PPL 70/8238,
70/7963, and PPL 80/2638. To assess MitoA uptake and distri-
bution in vivo, mice were placed in a heating chamber set to
38 °C (Vet-Tech Solutions) for 5 min, inserted in a rodent
restrainer with free access to the tail, andMitoA (50 nmol) was
injected into a lateral tail vein in 100 l of saline through a
27-gauge needle connected to a 1-ml syringe. Mice were then
monitored throughout the incubation period until time points
for tissue collection were reached.
For the ex vivo incubation of hearts, mice were anesthetized
with isoflurane (Abbott Laboratories, US) and oxygen at 2
liters/min. MitoA (50 nmol) was administered in saline via
the inferior vena cava and then the heart was explanted as
described (68). In brief, 100 l of heparin was administered
prior to exsanguination by division of the inferior vena cava and
aorta. The inferior vena cava, hemiazygous vein, superior vena
cava, innominate, left carotid, and left brachiocephalic were
ligated prior to division of the descending aorta, pulmonary
artery, and pulmonary veins. The heart was perfused with 500
l of ice-cold Soltran (Baxter Healthcare, UK). During dissec-
tion and ligation of vessels the heart was topically cooled with
4 °C saline every 2 min. This process took 12 min and the heart
was excised and stored in 10 ml of Belzer UW Cold Storage
Solution, University of Wisconsin solution (Belzer UW Cold
Storage Solution, Bridge to Life Ltd.) on ice for 240min or snap
frozen immediately. Samples were stored at 80 °C until
extraction for LC-MS/MS.
In vivo IRI was performed by using an open-chest, in situ
mouse (C57BL/6J) heart model in which the LAD is surgi-
cally transiently occluded as recently described (69). Mice
were anesthetized (pentobarbital sodium; 70 mg/kg; intra-
peritoneal (i.p.)), intubated endotracheally, and ventilated
with 3 cm of H2O positive end-expiratory pressure (110
breaths per min, 125–150 ml tidal volume) using a mouse
ventilator (MINIVENT Type 845, Harvard Apparatus, Ger-
many). Body temperature was monitored by rectal probe and
maintained at 37 °C via an animal temperature controller
(TCAT-2LV, Physitemp, Clifton, NJ). Corneal and withdraw
reflexes were checked for anesthesia depth and additional anes-
thesia was administered throughout the experimental protocol
if needed. A left thoracotomy was performed and the heart was
exposed via stripping of the pericardium. Regional ischemia
was then induced via ligation of the main branch of the LAD.
Successful occlusion was confirmed by color change of the
anterior wall of the left ventricle and apex from a bright red
color typical of a perfused heart to off-white and ischemia was
sustained for 30 min, at which point the tissue was reperfused.
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Reperfusion of the heart was confirmed by a color change of the
ischemic zone to red. Control mice were sham treated. MitoA
(50 nmol) was administered as a 100-l bolus via the tail vein at
various times during the procedure. Tissue was collected, snap
frozen, and stored at80 °C until analysis.
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Fig. S1  (A) Synthesis of MitoA and MitoN. ACN = acetonitrile, DIC = N, N’-
diisopropylcarbodiimide. (B) Control compounds 4 and 5 lacking the TPP targeting 
group were also prepared.Coupling of hexylamine with 4-azidobenzoic acid was achieved 
using N,N,N ,N -tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate 
(HBTU) to give amide 4, which was then hydrogenated to give the amine 5. 
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Fig. S2  Mass spectra of MitoA and MitoN. Observed (black) and simulated peaks 
(pink) for: MitoA, [C28H26N4OP]+ predicted m/z 465.1839. MitoA nitrene decomposition 
product from N2 neutral loss [C28H26N2OP]+ predicted m/z 437.1782 MitoN, 
[C28H29N2OP]+ predicted m/z 439.1934.Spectra were obtained using an ultra-high 
resolution electron spray time of flight mass spectrometer (maXis Bruker Daltonics).  
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Fig. S3  Reactivity of MitoA with a persulfide. MitoA (10 M) was mixed with 
NAP-SSH (25 M) in KCl buffer, pH 7.2 at 37 °C. Samples were taken at the indicated 
times and analysed by RP-HPLC. The amounts of MitoA and MitoN were determined by 
RP-HPLC from standard curves and used to calculate the amount of that compound as a 
percentage of the sum of MitoA and MitoN. The dashed line shows the amount of MitoN 
formed by incubating MitoA (10 M) NaS2 (25 M) in KCl buffer, pH 7.2 at 37 °C for 
60 min. 
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Fig. S4  Reactivity of MitoA with H2S during extraction for mass spectrometry 
MitoA (10 µM) was incubated with NaHS (10 µM) for 4 h in 95 % ACN. After the 
incubation, samples were dried under vacuum, resuspended in 20 % ACN, 0.1 % FA with 
internal standards and the amounts of MitoA, MitoN and the MitoN/MitoA ratio were 
quantified by LC-MS/MS. Data are means ± SEM, n = 4. *p < 0.05; two-tailed t-test.  
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Fig. S5  Effect of MitoA and MitoN on cell proliferation. C2C12 cells were  
plated at 10,000 cells per well in 6-well plates (~1 000 cells per cm2) and treating with 
MitoA or MitoN.Cell proliferation was then monitored by measuring confluency via 
automated bright field imaging (IncuCyte HD, EssenBioScience) for 144 h. Data are 
means ± SEM, n = 3. 
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Supplementary Experimental Procedures 
 
Chemical syntheses 
All reactions under an inert atmosphere were carried out using oven-dried or flame-
dried glassware and solvents were added via syringe. Reagents were obtained from 
commercial suppliers and used without further purification. Dry solvents were 
collected from a Puresolv solvent purification system, obtained from commercial 
suppliers or dried in the laboratory. Ethanol was distilled from Mg turnings activated 
with iodine. 1H NMR spectra were obtained using Bruker DPX/400 and Bruker-Avance 
III spectrometers operating at 400 and 500 MHz, 13C NMR spectra at 101 and 126 
MHz respectively. Signal splitting patterns were described as: singlet (s), doublet (d), 
triplet (t), quartet (q), multiplet (m), broad singlet (s, broad), or any combination of 
the above. All coupling constants were recorded in Hz. DEPT was used to assign the 
signals in 13C NMR spectra as C, CH, CH2 and CH3.  
 
 (3-Iodopropyl)triphenylphosphonium iodide (1) 
  
1,3-Diiodopropane (2.65 mL, 23 mmol) was added to a stirred solution of 
triphenylphosphine (3.01 g, 11.5 mmol) in toluene (25 mL) at 95 °C and the mixture 
was stirred for 20 h under reflux. After cooling to RT, the precipitate was collected by 
filtration and washed with Et2O, after this, it was dried under reduced pressure to 
yield the alkyl iodide 1 as a white amorphous solid. (5.98 g, 93%). Mp: 172-174 °C. 
νmax (ATR): 3056 (CH), 2916 (CH), 2849 (CH), 1587 (Ar). δH (CDCl3, 400 MHz): 
7.81-7.76 (9H, m, 6 o-H PPh3, 3 p-H PPh3), 7.71-7.66 (6H, m, 6 m-H PPh3), 3.92-3.84 
(2H, m, P-CH2), 3.56 (2H, t, J = 6.4 Hz, I-CH2), 2.19-2.10 (2H, m, CH2-CH2-CH2). δC 
(CDCl3, 125 MHz): 135.61 (d, J = 2.8 Hz, CH), 134.00 (d, J = 10.1 Hz, CH), 130.93 
(d, J = 12.8 Hz, CH), 118.01 (d, J = 86.1 Hz, C), 27.08 (d, J = 1.8 Hz, CH2), 24.41 (d, 
J = 51.3 Hz, CH2), 6.96 (d, J = 20.1 Hz, CH2). LRMS (ESI+) 431 [M+ (phosphonium 
cation), 100%]. HRMS (ESI+): 430.9137. C21H21IP requires M+ (phosphonium 
cation), 430.9117. 
 
(3-Iodoprop-1-yl)-tri(pentadeuterophenyl)phosphonium iodide (d15-1) 
  
1,3-Diiodopropane (500 µL, 4.3 mmol) was added to a stirring solution of d-15 
triphenylphosphine (500 mg, 1.8 mmol) in toluene (10 mL) at 95 °C and the mixture was 
set to react for 20 h under reflux conditions. After cooling to RT, the precipitate was 
collected by filtration and washed with Et2O, after this, it was dried under reduced 
pressure to yield the alkyl iodide d15-1 as a white amorphous solid. (1.01 g, 98%). Mp: 
173-175 °C. νmax (ATR): 2859 (CH), 2343 (CD), 1559 (Ar). δH (CDCl3, 500 MHz): 3.97-
3.91 (2H, m, P-CH2), 3.60 (2H, t, J = 6.5, I-CH2), 2.21-2.14 (2H, m, CH2-CH2-CH2). δC 
(CDCl3, 125 MHz): 135.11-134.73 (m, CD), 133.65-133.16 (m, CD), 130.50-129.99 (m, 
CD), 117.2 (d, J = 86.2 Hz, C), 26.90 (d, J = 2.0 Hz, CH2), 24.24 (d, J = 51.2 Hz, CH2), 
6.77 (d, J = 20.0 Hz, CH2). LRMS (ESI+) 446 [M+ (phosphonium cation), 100%] HRMS 
(ESI+): 446.1351. C21H6D15IP requires M+ (phosphonium cation), 446.1362. 
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(3-Azidoprop-1-yl)triphenylphosphonium iodide (2) 
  
A solution of (3-iodoprop-1-yl)triphenylphosphonium iodide 1 (5.02 g, 9.0 mmol) and 
NaN3 (1.17 g, 18.0 mmol) in EtOH (15.0 mL) and H2O (15.0 mL) was stirred and 
heated to 70 °C for 24 h. After cooling, an extraction was carried out with CHCl3 (3 
30 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure to yield the alkyl azide 2 as an amorphous beige 
solid (4.13 g, 97%). MP: 151-153 °C δH (CDCl3, 400 MHz): 7.85-7.79 (9H, m, 6 o-H 
PPh3, 3 p-H PPh3), 7.73-7.68 (6H, m, 6 m-H PPh3), 3.95-3.87 (2H, m, P-CH2), 3.82 
(2H, t, J = 6.2 Hz, N3-CH2), 1.95-1.86 (2H, m, CH2-CH2-CH2). δC (CDCl3, 100 
MHz): 135.57 (d, J = 2.9 Hz, CH), 133.95 (d, J = 10.3 Hz, CH), 130.92 (d, J = 12.5 
Hz, CH), 118.05 (d, J = 86.6 Hz, C), 50.98 (d, J = 17.6 Hz, CH2), 22.92 (d, J = 2.9 
Hz, CH2), 20.70 (d, J = 52.8 Hz, CH2). 1H and 13C NMR data agree with those for the 
bromide salt 1. 
 
 (3-Azidoprop-1-yl)-tri(pentadeuterophenyl)phosphonium iodide (d15-2) 
  
A solution of alkyl iodide d15-1 (1.00 g, 1.74 mmol) and NaN3 (260 mg, 4.0 mmol) in 
EtOH (5.0 mL) and H2O (5.0 mL) was stirred and heated to 70 °C for 24 h. After 
cooling, an extraction was carried out with DCM (3 30 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure to 
yield the alkyl azide d15-2 as an amorphous beige solid (825 mg, 97%). Mp: 151-153 
°C. νmax (ATR): 2888 (CH), 2796 (CH), 2362 (CD), 2110 (N3), 1546 (Ar). δH (CDCl3, 
500 MHz): 3.83-3.76 (4H, m, P-CH2, N3-CH2), 1.91-1.83 (2H, m, CH2-CH2-CH2). δC 
(CDCl3, 125 MHz): 134.99-134.60 (m, CD), 133.47-132.98 (m, CD), 130.40-129.91 
(m, CD), 117.40 (d, J = 86.2 Hz, C), 50.71 (d, J = 17.5 Hz, CH2), 22.63 (d, J = 2.6 
Hz, CH2), 20.33 (d, J = 52.9 Hz, CH2). LRMS (ESI+) 361 [M+ (phosphonium cation), 
34%], 333 [M+ (phosphonium cation) – N2, 100%]. HRMS (ESI+): 361.2395. 
C21H6D15N3P requires M+ (phosphonium cation), 361.2409. 
 
(3-Aminoprop-1-yl)triphenylphosphonium iodide (3) 
  
A solution of alkyl azide 2 (4.10 g, 8.7 mmol) and 10% Pd/C (425 mg, 4.0 mmol) in 
MeOH (40 mL) was stirred at RT under a H2 (1 atm) atmosphere for 6 h. After this 
time, the mixture was filtered through Celite®. Then, the mixture was concentrated 
under reduced pressure to yield the amine 3 as an amorphous beige solid (3.62 g, 
93%). Mp: 212-214 °C. νmax (ATR): 3050 (NH), 2887 (CH), 2789 (CH), 1586 (Ar). 
δH (CDCl3, 400 MHz): 7.83-7.76 (9H, m, 6 o-H PPh3, 3 p-H PPh3), 7.71-7.66 (6H, m, 
6 m-H PPh3), 3.78-3.71 (2H, m, P-CH2), 3.01 (2H, t, J = 6.2 Hz, NH2-CH2), 1.88 (2H, 
s, NH2), 1.82-1.72 (2H, m, CH2-CH2-CH2). δC (CDCl3, 100 MHz): 135.38 (d, J = 2.9 
Hz, CH), 133.99 (d, J = 9.7 Hz, CH), 130.84 (d, J = 12.6 Hz, CH), 118.48 (d, J = 85.5 
Hz, C), 41.74 (d, J = 17.5 Hz, CH2), 26.13 (d, J = 4.9 Hz, CH2), 21.14 (d, J = 51.5 Hz, 
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CH2). LRMS (ESI+) 320 [M+ (phosphonium cation), 100%], HRMS (ESI+): 320.1553. 
C21H23NP requires M+ (phosphonium cation), 320.1563. 
 
(3-Aminopropyl)-tri(pentadeuterophenyl)phosphonium iodide (d15-3) 
  
A solution of alkyl azide d15-2 (820 mg, 1.68 mmol) and 10% Pd/C (100 mg, 0.94 
mmol) in MeOH (10 mL) was stirred at RT under a H2 (1 atm) atmosphere for 6 h. 
After this time, the mixture was filtered through Celite®. Then, the mixture was 
concentrated under reduced pressure to yield the amine d15-3 as an amorphous beige 
solid (671 mg, 86%). Mp: 211-213 °C. νmax (ATR): 2950 (NH), 2887 (CH), 2789 
(CH), 2251 (CD), 1547 (Ar). δH (CDCl3, 400 MHz): 3.79-3.72 (2H, m, P-CH2), 3.01 
(2H, t, J = 6.3 Hz, NH2-CH2), 1.80-1.71 (2H, m, CH2-CH2-CH2), 1.48 (2H, s, NH2). 
δC (CDCl3, 100 MHz): 135.04-134.48 (m, CD), 133.70-133.09 (m, CD), 130.50-
129.84 (m, CD), 118.15 (d, J = 85.7 Hz, C), 41.65 (d, J = 17.5 Hz, CH2), 26.18 (d, J = 
2.5 Hz, CH2), 21.01 (d, J = 52.7 Hz, CH2). LRMS (ESI+) 335 [M+ (phosphonium 
cation), 100%]. HRMS (ESI+): 335.2489. C21H8D15NP requires M+ (phosphonum 
cation), 335.2504. 
 
 [3-(4’-Azidobenzamido)-prop-1-yl]triphenylphosphonium mesylate (MitoA, mesylate 
salt) 
  
A solution of 3 (2.24 g, 5.0 mmol), 4-azidobenzoic acid (816 mg, 5.0 mmol), and N, 
N’-diisopropylcarbodiimide (800 µl, 5.2 mmol) in dry ACN (20 mL) was stirred at 
RT under argon for 48 h. After this, the precipitate was washed with ACN (5 × 10 
mL). The precipitate was dried under high vacuum to remove the solvent, resulting in 
a brown powder. The powder was then treated for ion exchange with ion exchange 
resin Araldite® IRA-400 charged with mesylate ions giving a brown amorphous solid 
after solvent was removed. Column chromatography [SiO2, DCM-MeOH (95:5)] 
yielded the mesylate salt of MitoA as a brown amorphous solid (1.34 g, 47%). Rf 
[SiO2, DCM-MeOH (95:5)]: 0.25. Mp: 157-159 °C. νmax (ATR): 3289 (NH), 3063 
(CH), 2928 (CH), 2901 (CH), 2120 (N3), 1653 (C=O), 1601 (Ar), 1530 (Ar), 1497 
(Ar) cm–1. δH (CDCl3, 400 MHz): 9.28 (t, J = 5.9 Hz, NH), 8.15 (2H, d, J = 8.9 Hz, 
H-2’, H-6’), 7.76-7.69 (9H, m, 3 × p-H PPh3, 6 x o-H PPh3), 7.64 – 7.59 (6H, m, 6 m-
H PPh3), 7.07 (2H, d, J = 8.8 Hz, H-3’, H-5’), 3.75-3.67 (4H, m, P-CH2, NH-CH2), 
2.81 (3H, s, CH3SO3–), 1.98-1.90 (2H, m, CH2-CH2-CH2). δC (CDCl3, 100 MHz): 
167.10 (C), 142.99 (C), 135.13 (d, J = 2.0 Hz, CH), 133.57 (d, J = 9.1 Hz, CH), 
130.91 (C), 130.61 (d, J = 12.0 Hz, CH), 129.81 (CH), 118.92 (CH), 118.56 (d, J = 
86.0 Hz, C), 39.78 (CH3), 39.42 (d, J = 17.0 Hz, CH2), 22.60 (d, J = 4.0 Hz, CH2), 
20.16 (d, J = 52.1 Hz, CH2). LRMS (ESI+) 465 [M+ (phosphonium cation), 32%], 437 
[M+ (phosphonium cation) – N2, 100]. HRMS (ESI+): 465.1821. C28H26N4OP requires 
M+ (phosphonum cation), 465.1839 
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[3-(4’-Azidobenzamido)propyl]tri(pentadeuterophenyl)phosphonium mesylate (d15-
MitoA mesylate salt) 
 
A solution of amine d15-3 (100 mg, 0.22 mmol), 4-azidobenzoic acid (36 mg, 0.22 
mmol), and N, N’-diisopropylcarbodiimide (150 µl, 0.98 mmol) in dry ACN (2.5 mL) 
was stirred at RT under argon for 37 h. After this, the precipitate was washed with 
ACN (4 × 10 mL). The precipitate was dried under high vacuum to remove the 
solvent, resulting in a brown powder. The powder was then treated for ion exchange 
with ion exchange resin Araldite® IRA-400 charged with mesylate ions giving a 
brown amorphous solid after solvent was removed. Column chromatography [SiO2, 
DCM-MeOH (95:5)] yielded the target compound as a brown amorphous solid (57 
mg). As the mesylate ion was under integrated in the NMR, the solid was treated with 
aqueous NaMeSO3 (0.5 M) and extracted with DCM. The DCM was removed under 
reduced pressure to give the mesylate salt of d15-MitoA as a hygroscopic thick yellow 
oil (55 mg, 45%). Rf [SiO2, DCM-MeOH (95:5)]: 0.27. Mp: 156-158 °C. νmax (ATR): 
3283 (NH), 2935 (CH), 2906 (CH), 2823 (CH), 2269 (CD), 2120 (N3), 1644 (C=O), 
1603 (Ar), 1546 (Ar), 1500 (Ar). δH (CDCl3, 400 MHz): 9.10-9.08 (1H, m, NH), 7.98 
(2H, d, J = 8.6 Hz, H-2’, H-6’), 6.86 (2H, d, J = 8.6 Hz, H-3’, H-5’), 3.53-3.46 (4H, 
m, P-CH2, NH-CH2), 2.57 (3H, s, CH3SO3–), 1.83-1.81 (2H, m, CH2-CH2-CH2). δ 
(CDCl3, 100 MHz): 166.40 (C), 142.34 (C), 134.51-134.04 (m, CD), 132.96-132.36 
(m, CD), 130.41 (C), 130.01-129.41 (m, CD), 129.31 (CH), 118.40 (CH), 117.66 (d, J 
= 86.1 Hz, C), 39.29 (CH3), 39.06 (d, J = 17.0 Hz, CH2), 22.14 (d, J = 4.1 Hz, CH2), 
19.66 (d, J = 52.3 Hz, CH2). LRMS (ESI+) 480 [M+ (phosphonium cation), 30%], 452 
[M+ (phosphonium cation) – N2, 100]. HRMS (ESI+): 480.2760. C28H11D15N4OP+ 
requires M+ (phosphonum cation), 480.2780  
 
[3-(4’-Aminobenzamido)prop-1-yl]triphenylphosphonium mesylate (MitoN mesylate 
salt). 
  
A solution of amine 3 (1.12 g, 2.50 mmol), 4-aminobenzoic acid (340 mg, 2.47 
mmol), and N, N’-diisopropylcarbodiimide (400 µl, 2.68 mmol) in dry ACN (10 mL) 
was stirred at RT under argon for 48 h. After this, the precipitate was washed with 
ACN (5 × 10 mL). The precipitate was dried under high vacuum to remove the 
solvent, resulting in a beige powder. The powder was then treated for ion exchange 
with ion exchange resin Araldite® IRA-400 charged with mesylate ions giving a 
beige amorphous solid after solvent was removed. Column chromatography [SiO2, 
DCM-MeOH (9:1)] yielded the mesylate salt of MitoN as a beige amorphous solid 
(410 mg, 31%). Rf [SiO2, DCM-MeOH (9:1)]: 0.25. Mp: 206-208 °C. νmax (ATR): 
3333 (NH), 3225 (CH), 3059 (CH), 2931 (CH), 2904 (CH), 1628 (CO), 1603 (Ar), 
1545 (Ar), 1508 (Ar). δH (CDCl3, 400 MHz): 8.92 (t, J = 5.9 Hz, NH), 7.93 (2H, d, J 
= 8.6 Hz, H-2’, H-6’), 7.76-7.68 (9H, m, 3 × p-H PPh3, 6 × o-H PPh3), 7.63 – 7.59 
(6H, m, 6 × m-H PPh3), 6.66 (2H, d, J = 8.5 Hz, H-3’, H-5’), 4.07 (2H, s, NH2) 3.74-
3.67 (4H, m, P-CH2, NH-CH2), 2.83 (3H, s, CH3SO3–), 1.97-1.88 (2H, m, CH2-CH2-
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CH2). δC (CDCl3, 100 MHz): 167.74 (C), 149.59 (C), 134.92 (d, J = 2.3 Hz, CH), 
133.41 (d, J = 9.0 Hz, CH), 130.42 (d, J = 12.5 Hz, CH), 129.47 (C), 123.71 (CH), 
118.46 (d, J = 86.0 Hz, C), 114.07 (CH), 39.65 (CH3), 39.06 (d, J = 17.0 Hz, CH2), 
22.64 (d, J = 3.0 Hz, CH2), 19.79 (d, J = 52.0 Hz, CH2). LRMS (ESI+) 439 [M+ 
(phosphonium cation), 100%]. HRMS (ESI+): 439.1915. C28H28N2OP requires M+ 
(phosphonum cation), 439.1934. 
 
[3-(4’-Aminobenzamido)prop-1-yl]tri(pentadeuterophenyl)phosphonium mesylate (d15-
MitoN mesylate salt) 
  
A solution of amine d15-3 (100 mg, 0.22 mmol), 4-aminobenzoic acid (30 mg, 0.21 
mmol), and N, N’-diisopropylcarbodiimide (150 µl, 0.98 mmol) in dry ACN (2.5 mL) 
was stirred at RT under argon for 48 h. After this, the precipitate was washed with 
ACN (5 × 10 mL). The precipitate was dried under high vacuum to remove the 
solvent, resulting in a beige powder. The powder was then treated for ion exchange 
with ion exchange resin Araldite® IRA-400 charged with mesylate ions giving a 
beige amorphous solid after solvent was removed. Column chromatography [SiO2, 
DCM-MeOH (9:1)] yielded the amide d15-MitoN as a beige amorphous solid (50 mg, 
42%). As the mesylate ion was under integrated in the NMR, the solid was treated 
with aqueous NaMeSO3 (0.5 M) and extracted with DCM. The DCM was removed 
under reduced pressure to give the mesylate salt of d15-MitoN as a beige solid (38 mg, 
32%). Rf [SiO2, DCM-MeOH (9:1)]: 0.25. Mp: 207-209 °C. νmax (ATR): 3335 (NH), 
3228 (CH), 2931 (CH), 2902 (CH), 2281 (CD), 1623 (CO), 1599 (Ar), 1549 (Ar), 
1509 (Ar). δH (CD3OD, 400 MHz): 7.56 (2H, d, J = 8.8 Hz, H-2’, H-6’), 6.62 (2H, d, 
J = 8.8 Hz, H-3’, H-5’), 3.50-3.38 (4H, m, P-CH2, NH-CH2), 2.65 (3H, s, CH3SO3), 
1.96-1.86 (2H, m, CH2-CH2-CH2). δC CD3OD, (100 MHz): 170.54 (C), 153.45 (C), 
136.06-135.57 (m, CD), 134.64-134.05 (m, CD), 131.37-130.74 (m, CD), 130.02 (C), 
122.54 (CH), 119.54 (d, J = 86.4 Hz, C), 114.65 (CH), 40.78 (d, J = 19.0 Hz, CH2), 
39.52 (CH3), 23.99 (d, J = 3.7 Hz, CH2), 20.68 (d, J = 53.0 Hz, CH2). LRMS (ESI+) 
454 [M+ (phosphonium cation), 100%]. HRMS (ESI): 454.2855. C28H13D15N2OP 
requires M+ (phosphonum cation), 454.2875  
 
4’-Azido-N-(hex-1-yl)benzamide (4) 
  
Hex-1-ylamine (320 µL, 2.4 mmol), HBTU (835 mg, 2.2 mmol), and N-
methylmorpholine (NMM, 440 µL, 4 mmol) were added to a stirred solution of para-
azidobenzoic acid (367 mg, 2.2 mmol) in anhydrous DMF (10 mL) at RT under 
argon. Stirring was continued for 18 h, and then water (15 mL) was added. The 
precipitate was collected by filtration and washed with water (3 × 10 mL). The 
resulting solid was dried under high vacuum to give the amide 4 as an amorphous 
yellow solid (427 mg, 86%). Mp: 71-73 °C. νmax (ATR): 3312 (NH), 3075 (CH), 2955 
(CH), 2928 (CH), 2860 (CH), 2137 (N3), 1629 (CO), 1605 (Ar), 1545 (Ar), 1499 
(Ar). δH (CDCl3, 500 MHz): 7.76 (2H, d, J = 8.6 Hz, H-2’, H-6’), 7.05 (2H, d, J = 8.6 
Hz, H-3’, H-5’), 6.14 (1H, s, NH), 3.45-3.41 (2H, m, CH2-1), 1.60 (2H, qn, J = 7.0 
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Hz, CH2-2), 1.40-1.28 (6H, m, CH2-3, CH2-4, and CH2-5), 0.91-0.87 (3H, t, J = 7.0 
Hz, CH3). δC (CDCl3, 125 MHz): 166.57 (C), 143.30 (C), 131.53 (C), 128.78 (CH), 
119.03 (CH), 40.32 (CH2), 31.65 (CH2), 29.78 (CH2), 26.82 (CH2), 22.69 (CH2), 
14.16 (CH3). LRMS (EI+): 246 (M+•, 47%), 218 (M+• – N2, 100%), HRMS (EI+): 
246.1483. C13H18N4O requires M+•, 246.1481. 
 
4’-Amino-N-(hex-1-yl)benzamide (5) 
  
A solution of azide 4 (200 mg, 0.81 mmol) and 10% Pd/C (20 mg, 0.19 mmol) in 
MeOH (5 mL) was stirred at RT under a H2 (1 atm) atmosphere for 3 h. After this 
time, the mixture was filtered through Celite®. Then, the mixture was concentrated 
under reduced pressure to yield amine 5 as an amorphous beige solid (168 mg, 95%). 
Mp: 102-104 °C. νmax (ATR): 3410 (NH), 3329 (NH), 3215 (CH), 2955 (CH), 2924 
(CH), 2855 (CH), 1637 (C=O), 1601 (Ar), 1537 (Ar), 1504 (Ar). δH (CDCl3, 400 
MHz): 7.58 (2H, d, J = 8.6 Hz, H-2’, H-6’), 6.60 (2H, d, J = 8.6 Hz, H-3’, H-5’), 6.26 
(1H, broad s, NH), 4.05 (2H, s, NH2) 3.45-3.41 (2H, m, CH2-1]), 1.60 (2H, qn, J = 7.0 
Hz, CH2-2), 1.40-1.28 (6H, m, CH2-3, CH2-4 and CH2-5), 0.91-0.87 (3H, t, J = 7.0 
Hz, CH3). δC (CDCl3, 100 MHz): 166.57 (C), 152.43 (C), 133.65 (C), 128.88 (CH), 
117.88 (CH), 40.27 (CH2), 31.63 (CH2), 29.75 (CH2), 26.79 (CH2), 22.67 (CH2), 
14.14 (CH3). LRMS (ESI+) 243 [(M + Na)+, 100%] HRMS (ESI+): 243.1469. 
C13H20N2ONa requires (M + Na)+, 243.1468. IR data in broad agreement with Lit. 2.  
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